DIVISLAB Divi's Laboratories Q1 FY27 results (Apr–Jun 2026) and concall
Divi's Laboratories reported strong Q1 FY27 results with consolidated total income up 24.39% YoY and PAT up 65.50% YoY, driven by robust performance in Custom Synthesis and Nutraceuticals. The company continues to navigate a challenging external environment with elevated raw material costs and logistic issues through strategic inventory management and backward integration. Progress on dedicated capex projects and new product commercialization remains a key focus, particularly in the peptide and contrast media segments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 26.2%, net profit up 60.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,302 | 2,297 | 2,536 | 2,357 | 2,660 +16% | 2,578 +12% | 2,793 +10% | 2,974 +26% |
| EBITDA | 729 | 747 | 881 | 743 | 895 +23% | 907 +21% | 943 +7% | 1,240 +67% |
| Net profit | 518 | 594 | 667 | 557 | 696 +34% | 598 +1% | 756 +13% | 891 +60% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
